Welcome to our dedicated page for Ainos news (Ticker: AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.
Ainos, Inc. reports developments tied to its transition toward AI-powered scent intelligence and industrial sensing. The company centers its commercial focus on AI Nose, an electronic olfaction platform that uses sensor arrays and proprietary artificial intelligence models, including its Smell Language Model, to convert volatile organic compound and scent signals into machine-readable Smell ID data.
Recurring news themes include AI Nose commercialization across semiconductor manufacturing, robotics, smart infrastructure, and healthcare-related environments; distribution and deployment relationships; industry classification updates; and financial results connected to the platform. Ainos also maintains a therapeutic-development program around VELDONA, a low-dose oral interferon program targeting rare, autoimmune, and infectious diseases.
Ainos (NASDAQ:AIMD) reported first quarter 2026 results and updates on Smell AI commercialization. Operating expenses declined about 30% year-over-year to roughly US$2.28 million, and liquidity improved via a NT$90 million (≈US$2.8 million) financing. The company continued deploying its AI Nose platform under a roughly three-year US$2.1 million semiconductor arrangement targeting about 1,400 systems, expanded pilots in front-end chip fabs, and advanced healthcare infrastructure, robotics, and industrial use cases while growing its Smell ID datasets and Smell Language Model.
Ainos (NASDAQ:AIMD) updated its Standard Industrial Classification code from 2834 - Pharmaceutical Preparations to 3577 - Computer Peripheral Equipment, NEC, aligning with its focus on AI-powered sensing and Smell AI commercialization.
The change does not affect operations, finances, SEC reporting, Nasdaq listing, or strategy.
Ainos (NASDAQ:AIMD) announced expansion of its Smell AI deployments into healthcare infrastructure on April 17, 2026, building on existing semiconductor and robotics use cases.
Collaborations with MacKay Memorial Hospital and Topco Scientific target environmental monitoring across HVAC, power/electromechanical systems, chemical handling, and clinical labs, while the company advances its Smell ID and Smell Language Model to scale a data flywheel for repeatable deployments.
Ainos (NASDAQ:AIMD) announced a partnership with MacKay Memorial Hospital and Topco Scientific to deploy its AI Nose Smell AI platform in high-risk hospital environments starting April 2026. Initial deployment targets four core areas: power/electromechanical, gas/HVAC, chemical handling, and clinical labs including MRI suites.
The program aims to create a hospital-level environmental intelligence layer that models scent baselines, detects real-time anomalies, and supports earlier awareness of infection, chemical, and infrastructure risks while validating platform-level adoption and system integration.
Ainos (NASDAQ:AIMD) is moving from validation to execution with visible 2026 deployment momentum for its AI Nose Smell AI platform. Key metrics: 2025 revenue +499% YoY, 82.9% gross margin, ~99% revenue tied to AI Nose, a $2.1M three-year subscription for ~1,400 systems targeted Q2 2026, plus ~200 validation units and 600 committed systems, supported by $350k customer deposits and ~$2.82M in new financing.
Ainos (NASDAQ:AIMD) reported 2025 results showing ~499% revenue growth and a swing to positive gross margin of 82.9%. The company secured a New Taiwan Dollar 90 million financing (~USD $2.82M) and announced early 2026 semiconductor deployments: ~200 front-end systems and 1,400 systems under a three-year $2.1M program with deposits received and a roadmap to 20,000 systems.
Management emphasized scaled AI Nose commercial deployments, recurring Smell ID and Smell Language Model monetization, and disciplined capital allocation entering 2026.
Ainos (NASDAQ:AIMD) is advancing commercial deployment of its AI Nose digital olfaction platform, highlighted in The Wall Street Journal piece on emerging "Smell AI." The company has a signed deployment of 1,400 systems in backend semiconductor environments and is targeting up to 20,000 systems as a longer-term roadmap. Ainos is also pursuing ~200 systems for front-end wafer fabs and early integrations with robotic and quadruped inspection platforms. The company emphasizes multi-year growth potential, recurring revenue models, and development of Smell Tech data infrastructure.
Ainos (NASDAQ:AIMD) is scaling AI Nose deployments across semiconductor manufacturing, with front-end and back-end initiatives driving recurring subscription revenue.
Key metrics: ~200 systems planned for front-end wafer fabs in 1Q26, 1,400 Phase 1 systems for ASE completing in 2Q26, generating ≈$2.1M over three years and a potential $10M annual subscription run‑rate if a 20,000‑system roadmap executes.
Ainos (NASDAQ:AIMD) announced continued validation of its AI Nose platform in front-end wafer fabs with ~200 targeted deployments planned in Q1 2026 for technical validation.
It is executing Phase 1 of a 1,400-system back-end deployment worth approximately $2.1 million under a three-year subscription, targeting completion in Q2 2026. The broader roadmap contemplates up to 20,000 systems, which the company says could approach $10 million in annual subscription value, all subject to technical validation and contractual conversion. Management says milestones and subscription activation plans remain unchanged despite market volatility.
Ainos (NASDAQ:AIMD) outlined a phased deployment plan for up to 20,000 AI Nose systems, anchored by a confirmed initial order of 1,400 systems.
The initial order activates recurring subscription revenue under a three-year service structure totaling approximately $2.1 million, and the roadmap states potential annual order values approaching $10 million if fully executed, subject to staged technical validation and formal contractual conversion.
Validation testing is underway in advanced semiconductor front-end fabrication environments to support commercial integration and multi-site industrial scaling.